查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566754

人用胰岛素市场：按产品类型、按适应症、按胰岛素类型、按分销管道：2024-2033 年全球机会分析和产业预测

Human Insulin Market By Product Type, By Indication By Type of Insulin By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 245 Pages | 商品交期: 2-3个工作天内

价格
简介目录

人类胰岛素市场

2023年，人胰岛素市值为171亿美元，预计2024年至2033年复合年增长率为3.4%，到2033年达到240亿美元。

人类胰岛素是天然胜肽激素的合成模拟物，是在实验室的大肠桿菌中合成的。有一种短效常规形式和一种称为神经鱼精蛋白哈格多恩胰岛素的中间形式。人类胰岛素取代人体自然产生的胰岛素并调节血液中的血糖浓度。

人类胰岛素市场的关键驱动因素是全球糖尿病盛行率的不断上升。与动物胰岛素相比，人类胰岛素因其功效高且过敏反应风险极低而受到患者和医生的快速需求。人类胰岛素市场的最新趋势是，由于疗效可比且成本效益更高，患者倾向于使用生物相似药产品。

然而，其他替代品的存在，例如含有 GLP-1 受体促效剂的口服药物和非胰岛素注射药物，对人类胰岛素产生了显着的竞争。此外，由于临床前阶段、临床试验和上市后安全监测等各阶段的监管核准程序冗长，将人类胰岛素推向市场是一个复杂且耗时的过程。这延迟了蛋白质的供应并限制了市场的开拓。相反，人工智慧和机器学习等资料主导方法的整合有望透过优化生产参数和预测产品产量来提高生产效率。

按部门审查

人类胰岛素市场分为产品类型、适应症、胰岛素类型、通路和地区。依产品类型划分，市场分为笔、注射器等。依适应症分为第1型糖尿病、第2型糖尿病和妊娠糖尿病。胰岛素依类型分为速效胰岛素、短效胰岛素、中效胰岛素等。依分销管道分为医院药房、药局和零售药房以及线上供应商。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按产品类型划分，钢笔细分市场将在 2023 年占据主导地位。

有迹象表明，1 型糖尿病细分市场将在 2023 年取得较高的市场地位。

按胰岛素类型划分，速效胰岛素细分市场在 2023 年获得了较高的市场占有率。

按分销通路划分，药局/零售药局细分市场在 2023 年占据最高份额。

按地区划分，北美地区 2023 年收益最高。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章依产品类型分類的人类胰岛素市场

  • 市场概况
  • 笔
  • 注射器
  • 其他的

第五章人类胰岛素市场：依适应症分类

  • 市场概况
  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第六章 人用胰岛素市场：按胰岛素类型

  • 市场概况
  • 速效胰岛素
  • 短效胰岛素
  • 中效胰岛素
  • 其他的

第七章人胰岛素市场：依通路分类

  • 市场概况
  • 医院药房
  • 药局和零售药局
  • 线上提供者

第八章人类胰岛素市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国胰岛素市场
    • 加拿大人胰岛素市场
    • 墨西哥人胰岛素市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国人胰岛素市场
    • 法国人胰岛素市场
    • 英国胰岛素市场
    • 义大利人胰岛素市场
    • 西班牙人胰岛素市场
    • 其他欧洲人胰岛素市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本人胰岛素市场
    • 中国人胰岛素市场
    • 印度人胰岛素市场
    • 澳洲人胰岛素市场
    • 韩国人胰岛素市场
    • 其他亚太地区人类胰岛素市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西人胰岛素市场
    • 沙乌地人胰岛素市场
    • 南非人胰岛素市场
    • 其他拉丁美洲/中东/非洲人胰岛素市场

第9章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第十章 公司简介

  • Eli Lilly And Company
  • Sanofi
  • Novo Nordisk A/S
  • Pfizer
  • Biocon
  • Wockhardt
  • MannKind Corporation
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Medtronic
  • Lupin
简介目录
Product Code: A00321

Human Insulin Market

The human insulin market was valued at $17.1 billion in 2023 and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.

Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.

A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.

However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.

Segment Review

The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the pens segment dominated the market in 2023.

As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.

Depending on type of insulin, the rapid-acting insulin segment garnered a high market share in 2023.

According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the global human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Pens
  • Syringes
  • Others

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Type Of Insulin

  • Rapid-acting insulin
  • Short-acting insulin
  • Intermediate-acting insulin
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • Pfizer
    • Biocon
    • Wockhardt
    • MannKind Corporation
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Medtronic
    • Lupin

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: HUMAN INSULIN MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Pens
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Syringes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: HUMAN INSULIN MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Type 1 Diabetes
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Type 2 Diabetes
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Gestational Diabetes
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HUMAN INSULIN MARKET, BY TYPE OF INSULIN

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Type of Insulin
  • 6.2. Rapid-acting Insulin
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Short-acting Insulin
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Intermediate-acting Insulin
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: HUMAN INSULIN MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Product Type
    • 8.2.3. Market Size and Forecast, By Indication
    • 8.2.4. Market Size and Forecast, By Type of Insulin
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Human Insulin Market
      • 8.2.7.1. Market Size and Forecast, By Product Type
      • 8.2.7.2. Market Size and Forecast, By Indication
      • 8.2.7.3. Market Size and Forecast, By Type of Insulin
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Human Insulin Market
      • 8.2.8.1. Market Size and Forecast, By Product Type
      • 8.2.8.2. Market Size and Forecast, By Indication
      • 8.2.8.3. Market Size and Forecast, By Type of Insulin
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Human Insulin Market
      • 8.2.9.1. Market Size and Forecast, By Product Type
      • 8.2.9.2. Market Size and Forecast, By Indication
      • 8.2.9.3. Market Size and Forecast, By Type of Insulin
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Product Type
    • 8.3.3. Market Size and Forecast, By Indication
    • 8.3.4. Market Size and Forecast, By Type of Insulin
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Human Insulin Market
      • 8.3.7.1. Market Size and Forecast, By Product Type
      • 8.3.7.2. Market Size and Forecast, By Indication
      • 8.3.7.3. Market Size and Forecast, By Type of Insulin
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Human Insulin Market
      • 8.3.8.1. Market Size and Forecast, By Product Type
      • 8.3.8.2. Market Size and Forecast, By Indication
      • 8.3.8.3. Market Size and Forecast, By Type of Insulin
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Human Insulin Market
      • 8.3.9.1. Market Size and Forecast, By Product Type
      • 8.3.9.2. Market Size and Forecast, By Indication
      • 8.3.9.3. Market Size and Forecast, By Type of Insulin
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Human Insulin Market
      • 8.3.10.1. Market Size and Forecast, By Product Type
      • 8.3.10.2. Market Size and Forecast, By Indication
      • 8.3.10.3. Market Size and Forecast, By Type of Insulin
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Human Insulin Market
      • 8.3.11.1. Market Size and Forecast, By Product Type
      • 8.3.11.2. Market Size and Forecast, By Indication
      • 8.3.11.3. Market Size and Forecast, By Type of Insulin
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Human Insulin Market
      • 8.3.12.1. Market Size and Forecast, By Product Type
      • 8.3.12.2. Market Size and Forecast, By Indication
      • 8.3.12.3. Market Size and Forecast, By Type of Insulin
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Product Type
    • 8.4.3. Market Size and Forecast, By Indication
    • 8.4.4. Market Size and Forecast, By Type of Insulin
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Human Insulin Market
      • 8.4.7.1. Market Size and Forecast, By Product Type
      • 8.4.7.2. Market Size and Forecast, By Indication
      • 8.4.7.3. Market Size and Forecast, By Type of Insulin
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Human Insulin Market
      • 8.4.8.1. Market Size and Forecast, By Product Type
      • 8.4.8.2. Market Size and Forecast, By Indication
      • 8.4.8.3. Market Size and Forecast, By Type of Insulin
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Human Insulin Market
      • 8.4.9.1. Market Size and Forecast, By Product Type
      • 8.4.9.2. Market Size and Forecast, By Indication
      • 8.4.9.3. Market Size and Forecast, By Type of Insulin
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Human Insulin Market
      • 8.4.10.1. Market Size and Forecast, By Product Type
      • 8.4.10.2. Market Size and Forecast, By Indication
      • 8.4.10.3. Market Size and Forecast, By Type of Insulin
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Human Insulin Market
      • 8.4.11.1. Market Size and Forecast, By Product Type
      • 8.4.11.2. Market Size and Forecast, By Indication
      • 8.4.11.3. Market Size and Forecast, By Type of Insulin
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Human Insulin Market
      • 8.4.12.1. Market Size and Forecast, By Product Type
      • 8.4.12.2. Market Size and Forecast, By Indication
      • 8.4.12.3. Market Size and Forecast, By Type of Insulin
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Product Type
    • 8.5.3. Market Size and Forecast, By Indication
    • 8.5.4. Market Size and Forecast, By Type of Insulin
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Human Insulin Market
      • 8.5.7.1. Market Size and Forecast, By Product Type
      • 8.5.7.2. Market Size and Forecast, By Indication
      • 8.5.7.3. Market Size and Forecast, By Type of Insulin
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Human Insulin Market
      • 8.5.8.1. Market Size and Forecast, By Product Type
      • 8.5.8.2. Market Size and Forecast, By Indication
      • 8.5.8.3. Market Size and Forecast, By Type of Insulin
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Human Insulin Market
      • 8.5.9.1. Market Size and Forecast, By Product Type
      • 8.5.9.2. Market Size and Forecast, By Indication
      • 8.5.9.3. Market Size and Forecast, By Type of Insulin
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Human Insulin Market
      • 8.5.10.1. Market Size and Forecast, By Product Type
      • 8.5.10.2. Market Size and Forecast, By Indication
      • 8.5.10.3. Market Size and Forecast, By Type of Insulin
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Eli Lilly And Company
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Sanofi
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Novo Nordisk A/S
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Pfizer
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Biocon
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Wockhardt
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. MannKind Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Medtronic
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Lupin
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments